**Appendix Table D72. Risk of bias in randomized controlled clinical trials that examined comparative effectiveness of topiramate for migraine prevention in adults**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Masking of the Treatment Status** | **Intention to Treat Analysis Preplanned** | **Allocation Concealment** | **Adequacy of Randomization** | **Selective Outcome Reporting** | **Risk of Bias** |
| Bartolini, 2005166 | Open-label | Not reported | Unclear | No (Females were more in the valproate group and males in the topiramate group) | Unclear | High |
| Shaygannejad, 2006167 | Double-blind | Yes | Unclear | No (sodium valproate group had slightly more severe headache and lower duration of migraine than topiramate group) | Unclear | Medium |
| Gupta, 200744 | Double-blind | Yes | Unclear | Unclear | Unclear | Low |
| de Tommaso, 2007168 | Double-blind | No | Unclear | Not reported | Unclear | Medium |
| Milan-Guerrero, 2008169 | Double-blind | No | Unclear | Yes | Unclear | Low |
| Keskinbora, 2008170 | Double-blind | No | Unclear | Yes | Unclear | Medium |
| Ashtari, 2008171 | Double-blind | No | Unclear | Yes | Unclear | Medium |
| Dodick, 2009172 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Mohammadianinejad, 2011173 | Double-blind | No | Clearly adequate | Yes | Unclear | Medium |